PROMONTORY THERAPEUTICS
Promontory Therapeutics Inc. is a clinical stage pharmaceutical company developing small molecule immunotherapies. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death as well as osteotropism that confers advantages in dealing with cancers that originate in or metastasize to the bone. Clinical data generated to date across three Phase 1 studies have demonstrated single-agent ... anti-cancer activity and an attractive tolerability profile, and three Phase 2 studies of PT-112 are underway. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active collaborative research and development agreement (CRADA) with the NCI to conduct a Phase 2 trial utilizing PT-112 in thymic epithelial tumors.
PROMONTORY THERAPEUTICS
Industry:
Biotechnology Life Science Oncology Pharmaceutical
Founded:
2010-11-15
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.promontorytx.com
Total Employee:
11+
Status:
Active
Contact:
+1 646 380-2441
Total Funding:
72.01 M USD
Technology used in webpage:
SPF Amazon Organization Schema Google Apps For Business GoDaddy DNS AWS Global Accelerator
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Vittoria Biotherapeutics
Vittoria Biotherapeutics is a gene-edited cell therapeutics company.
Current Employees Featured
Stan Musial Chief Financial Officer @ Promontory Therapeutics
Chief Financial Officer
2022-11-01
Robert E. Fallon President, CEO and co-Founder @ Promontory Therapeutics
President, CEO and co-Founder
Kate Hogg Call Vice President of Clinical Operations @ Promontory Therapeutics
Vice President of Clinical Operations
2022-09-01
Johan Baeck Executive Vice President and Chief Medical Officer @ Promontory Therapeutics
Executive Vice President and Chief Medical Officer
2022-05-01
Helene Shea Vice President CMC @ Promontory Therapeutics
Vice President CMC
2022-07-01
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2022-11-28 | Promontory Therapeutics Appoints Stan Musial as Chief Financial Officer |
| 2022-09-13 | Promontory Therapeutics Appoints Two Experienced Executives to Its Core Management Team |
Official Site Inspections
http://www.promontorytx.com Semrush global rank: 15.84 M Semrush visits lastest month: 1
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Promontory Therapeutics"
Leadership | Promontory Therapeutics | Advancing small molecule ...
Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a …See details»
Promontory Therapeutics - Crunchbase Company Profile & Funding
Promontory Therapeutics Inc. is a clinical stage pharmaceutical company developing small molecule immunotherapies. The company's lead candidate, PT-112, is a novel chemical entity …See details»
Phosplatin Therapeutics Adopts New Corporate Name as …
May 5, 2022 To learn more about Promontory Therapeutics’ mission, as well as PT-112 visit promontorytx.com. About Promontory Therapeutics. Promontory Therapeutics Inc. is a …See details»
Promontory Therapeutics - LinkedIn
Promontory Therapeutics | 2,247 followers on LinkedIn. Phase 2 stage biotech company developing novel small-molecule anti-cancer immunotherapies. | Promontory Therapeutics is a …See details»
Phosplatin Therapeutics Adopts New Corporate Name …
May 5, 2022 To learn more about Promontory Therapeutics' mission, as well as PT-112 visit www.promontorytx.com. About Promontory Therapeutics. Promontory Therapeutics Inc. is a privately held, clinical stage ...See details»
Org Chart Promontory Therapeutics - The Official Board
For each of our 1,260,786 listed executives, discover their exact roles and their biographies.See details»
Promontory Therapeutics - BIO CEO & Investor Conference | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... https://promontorytx.com. …See details»
Promontory Therapeutics - Company Profile - Tracxn
Dec 5, 2024 Promontory Therapeutics - Developer of immunotherapeutics for the treatment of cancer. Raised a total funding of $72.3M over 3 rounds from 2 investors. Founded by Matthew …See details»
Promontory Therapeutics - VentureRadar
Website: https://promontorytx.com/ We are developing novel small molecules that engage an anti-cancer immune response. Our lead candidate, PT-112, is the first ever ...See details»
Overview, News & Similar companies - ZoomInfo.com
Mar 8, 2024 Promontory Therapeutics contact info: Phone number: (646) 380-2441 Website: www.promontorytx.com What does Promontory Therapeutics do? Promontory Therapeutics …See details»
Promontory Therapeutics Overview - Salary.com
Discover essential details about Promontory Therapeutics, including address, contact, and journey of our company's evolution.See details»
Promontory Therapeutics Appoints Two Experienced Executives to …
Sep 13, 2022 Helene Shea as Vice President of Chemistry, Manufacturing and Controls, and Kate Hogg Call as Vice President of Clinical Operations NEW YORK, Sept. 13, 2022 …See details»
Promontory Therapeutics, Inc. in New York, NY - (646) 380-2441
Promontory Therapeutics, Inc. is in the Biotechnical Research, Commercial business. View competitors, revenue, employees, website and phone number.See details»
promontorytx.com Reviews | scam, legit or safe check | Scamadviser
Check promontorytx.com with our free review tool and find out if promontorytx.com is legit and reliable. Need advice? Report scams Check Scamadviser! Report a Scam Help & Info API & …See details»
How much do Promontory Therapeutics employees make?
The average annual salary of Promontory Therapeutics is estimated to be approximate $113,338 per year. The majority pay is between $99,855 to $127,999 per year. Visit Salary.com to find …See details»
Careers | Promontory Therapeutics | Advancing small molecule …
Careers@promontorytx.com . Promontory Therapeutics. 1350 Avenue of the Americas, 23rd Floor New York, NY 10019 ...See details»
Promontory HOA | Heath, TX
For First time users, please Click here to obtain your Initial Login Information. The Promontory Homeowners Association in Heath, Texas welcomes you to our website. We use this site to …See details»
Texas border town wins $13M grant for environment work - The …
3 days ago Presidio, northwest of Big Bend National Park, will get dedicated green spaces along bike lanes and pedestrian streets, plant thousands of native trees and establish a high-school …See details»
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive …
May 16, 2022 Experienced physician with in-depth expertise in clinical development and immuno-oncology . NEW YORK, May 16, 2022 /PRNewswire/ -- Promontory Therapeutics …See details»
Promontory Therapeutics Selected as the First International …
Sep 29, 2023 Paris-Saclay Cancer Cluster was recently formed to become the leading European hub for research and innovation in oncology Promontory builds upon its recent expansion to …See details»